AU2012282825B2 - Method for detection of amyloid beta oligomers in a fluid sample and uses thereof - Google Patents

Method for detection of amyloid beta oligomers in a fluid sample and uses thereof Download PDF

Info

Publication number
AU2012282825B2
AU2012282825B2 AU2012282825A AU2012282825A AU2012282825B2 AU 2012282825 B2 AU2012282825 B2 AU 2012282825B2 AU 2012282825 A AU2012282825 A AU 2012282825A AU 2012282825 A AU2012282825 A AU 2012282825A AU 2012282825 B2 AU2012282825 B2 AU 2012282825B2
Authority
AU
Australia
Prior art keywords
antibody
oligomer
ndpoi
oligomers
bead
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012282825A
Other languages
English (en)
Other versions
AU2012282825A1 (en
Inventor
Alexander Mccampbell
Mary SAVAGE
Paul Shughrue
Abigail WOLFE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2012282825A1 publication Critical patent/AU2012282825A1/en
Application granted granted Critical
Publication of AU2012282825B2 publication Critical patent/AU2012282825B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
AU2012282825A 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof Active AU2012282825B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507332P 2011-07-13 2011-07-13
US61/507,332 2011-07-13
PCT/US2012/045886 WO2013009667A1 (en) 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof

Publications (2)

Publication Number Publication Date
AU2012282825A1 AU2012282825A1 (en) 2014-01-16
AU2012282825B2 true AU2012282825B2 (en) 2016-05-26

Family

ID=47506433

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012282825A Active AU2012282825B2 (en) 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof

Country Status (13)

Country Link
US (2) US20130052670A1 (cg-RX-API-DMAC7.html)
EP (2) EP2732286A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014521089A (cg-RX-API-DMAC7.html)
KR (1) KR20140072019A (cg-RX-API-DMAC7.html)
CN (1) CN103782171B (cg-RX-API-DMAC7.html)
AU (1) AU2012282825B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014000671A2 (cg-RX-API-DMAC7.html)
CA (1) CA2840976A1 (cg-RX-API-DMAC7.html)
DK (1) DK2732289T3 (cg-RX-API-DMAC7.html)
ES (1) ES2666840T3 (cg-RX-API-DMAC7.html)
MX (1) MX2014000480A (cg-RX-API-DMAC7.html)
RU (1) RU2014105172A (cg-RX-API-DMAC7.html)
WO (2) WO2013009667A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010262862C1 (en) 2009-06-17 2020-04-30 Biogen Ma Inc. Compositions and methods for modulation of SMN2 splicing in a subject
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
EP2943225A4 (en) 2013-01-09 2016-07-13 Ionis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR MODULATING SMN2 DISTRIBUTION IN THE BODY OF A PATIENT
KR20160079891A (ko) * 2013-11-20 2016-07-06 유니버시티 오브 아이오와 리써치 파운데이션 아밀로이드 침착의 치료를 위한 방법 및 조성물
WO2015161170A2 (en) 2014-04-17 2015-10-22 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
WO2016040748A1 (en) * 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for detection of smn protein in a subject and treatment of a subject
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
EP3341725B1 (en) * 2015-08-25 2021-08-18 Prothena Biosciences Limited Methods for detecting phosphorylated alpha-synuclein
CN108603880B (zh) 2016-02-08 2021-01-05 希森美康株式会社 受试物质的检测方法及受试物质的检测用试剂盒
WO2017218884A1 (en) 2016-06-16 2017-12-21 Ionis Pharmaceuticals, Inc. Combinations for the modulation of smn expression
US20220268789A1 (en) * 2019-07-05 2022-08-25 Shimadzu Corporation Monoclonal antibody against amyloid beta, and method for measuring amyloid beta-related peptide using said antibody
AU2021225957A1 (en) 2020-02-28 2022-09-08 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating SMN2
KR102798206B1 (ko) * 2021-06-25 2025-04-22 장재원 동적 형광 또는 x-선의 표준편차와 자기상관을 활용한 조기 진단 시스템
EP4399218A4 (en) * 2021-08-30 2025-10-29 Brigham & Womens Hospital Inc METHODS AND MATERIALS FOR TREATING A NEURODEGENERATIVE DISEASE
WO2024026413A2 (en) * 2022-07-27 2024-02-01 Durin Technologies, Inc. Early detection and monitoring of neurodegenerative diseases using a multi-disease diagnostic platform
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166035A1 (en) * 2009-11-24 2011-07-07 Probiodrug Ag Novel diagnostic method

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665024A (en) 1984-10-01 1987-05-12 Becton, Dickinson And Company Fluorescent gram stain
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6082205A (en) 1998-02-06 2000-07-04 Ohio State University System and device for determining particle characteristics
DE60016227T2 (de) 1999-08-04 2005-12-15 Northwestern University, Evanston Globularer aufbau vom amyloid-beta- protein und deren verwendungen
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
EP1717250A4 (en) 2004-02-20 2008-10-01 Immuno Biological Lab Co Ltd MONOCLONAL ANTIBODY AND ITS USE
WO2005096730A2 (en) * 2004-04-02 2005-10-20 Merck & Co., Inc. Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
JP5173426B2 (ja) * 2004-10-25 2013-04-03 メルク・シャープ・エンド・ドーム・コーポレイション 抗ａｄｄｌ抗体およびこの使用
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
CA2626783A1 (en) * 2005-10-21 2007-05-03 Merck & Co., Inc. Anti-addl monoclonal antibody and use thereof
US20090181359A1 (en) * 2007-10-25 2009-07-16 Lou Sheng C Method of performing ultra-sensitive immunoassays
EP2576617B1 (en) * 2010-06-04 2016-04-27 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
EP2593475B1 (en) * 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166035A1 (en) * 2009-11-24 2011-07-07 Probiodrug Ag Novel diagnostic method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D1 : US 2011/0166035 A1 (KLEINSCHMIDT ET AL) 07 July 2011 *
D2 : SANTOS ET AL:Journal of Alzheimer's disease, 2008, vol. 14, pages 127-131 *
D3 : PESARESI ET AL: "Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment". Neurobiology of Aging, 2006, vol. 27, pages 904-905 *

Also Published As

Publication number Publication date
ES2666840T3 (es) 2018-05-08
EP2732286A1 (en) 2014-05-21
BR112014000671A2 (pt) 2017-02-14
DK2732289T3 (en) 2018-05-22
CN103782171B (zh) 2016-12-14
MX2014000480A (es) 2014-06-23
WO2013009667A1 (en) 2013-01-17
CN103782171A (zh) 2014-05-07
RU2014105172A (ru) 2015-08-20
KR20140072019A (ko) 2014-06-12
AU2012282825A1 (en) 2014-01-16
CA2840976A1 (en) 2013-01-17
EP2732286A4 (en) 2015-02-25
EP2732289B1 (en) 2018-04-11
WO2013009703A2 (en) 2013-01-17
WO2013009703A8 (en) 2014-01-23
US20130052670A1 (en) 2013-02-28
EP2732289A2 (en) 2014-05-21
WO2013009703A3 (en) 2013-03-21
JP2014521089A (ja) 2014-08-25
US20140120037A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
AU2012282825B2 (en) Method for detection of amyloid beta oligomers in a fluid sample and uses thereof
AU2005306997B2 (en) Anti-ADDL antibodies and uses thereof
US20150023952A1 (en) Anti-addl monoclonal antibody and uses thereof
US9310383B2 (en) Antibodies, kit and method for detecting amyloid beta oligomers
TWI892069B (zh) 用於偵測Tau蛋白或其片段的方法與套組
JP2024534269A (ja) 神経変性疾患を治療するための方法および物質
AU2011204912B2 (en) Anti-ADDL antibodies and uses thereof
WO2025260029A1 (en) Method for quantifying amyloid beta protofibril
WO2026005695A1 (en) Detection of oligomeric tau and soluble tau aggregates
TW202344840A (zh) 診斷檢定
WO2025137532A1 (en) Method for quantifying amyloid beta protofibril
AU2012232964B2 (en) Anti-ADDL antibodies and uses thereof
WO2013115348A1 (ja) ｓＡＰＰβに対する抗体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)